Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
Investor overview Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy. What makes Scandion Oncology an attractive company for investors? Limited investment horizon: Clinical Phase II studies will be completed within few years after investment. Potential high return: Detailed
Bolaget utvecklar läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier visat sig förbättra effekten av viss standardcancerbehandling. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn. PRESS RELEASE. April 12, 2021. Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5%, Saniona has sold its remaining shares of Scandion Oncology A/S (Nasdaq First North Growth Market: SCOL) on the open market. As a result of these transactions, … Share price.
Scandion Oncology A/S SCOL - Scandion Oncology A/S Share Price. SEK17.05 -0.5 -2.6% Last Trade - 05/03/21. Sector Healthcare RiskRating. Speculative.
2020-06-16 10:30:54 Scandion Oncology A/S: Scandion Oncology has received a Eurostars grant of 800,000 EUR, shared with Erasmus Medical Centre, Rotterdam and 2cureX AB, for evaluating SCO-101 against antiestrogen resistance in breast cancer +12,32% | 13,5 MSEK
Stock analysis for Scandion Oncology A/S (1720681D) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Latest Scandion Oncology A/S (SCOL:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scandion Oncology A/S. Over the past six months, the relative strength of its shares against the market has been %.
Scandion Oncology A/S: Year-end Report 2020: Scandion Oncology is poised for the future; 29.1.2021 06.44 · Nyhetsbyrån Direkt SCANDION ONCOLOGY: ÄNDRING I PANTAX-STUDIE, EV FÖRSENING (OMS) 28.1.2021 22.02 · Nyhetsbyrån Direkt SCANDION ONCOLOGY: ÄNDRING I PANTAX-STUDIEN, SPÅR EV FÖRSENING; 28.1.2021 21.35 · Cision
Bolaget ingick tidigare i First North-noterade Saniona. Projektet kommer ursprungligen från danska Neurosearch som för flera år sedan sålde ut delar av sin verksamhet. Scandion genomför nu en nyemission på 26 Mkr inför listning på Spotlight The purchase price for each share in Scandion Oncology will be the volume weighted average price of the Company’s shares on Spotlight Stock Market during a period of ten (10) trading days after the publication of this press release with ten (10) percent discount. For further information regarding Scandion Oncology, please contact: The Board of Directors in Scandion Oncology A/S (”Scandion Oncology” or the ”Company”) has today, 16 November 2020, pursuant to the authorization granted by the extraordinary general meeting on 13 November 2020, resolved on a fully guaranteed new share issue of 10,711,848 shares with preferential rights for the Company’s existing shareholders (the ”Rights Issue”). 2021-04-01 · View the latest Scandion Oncology A/S (SCOL) stock price, news, historical charts, analyst ratings and financial information from WSJ. PRESS RELEASE April 12, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5%, Saniona has sold its remaining shares of Scandion Oncology A/S (Nasdaq First North Growth Market: SCOL) on the open market.
Earnings Per Share-1.17: with the exception of the current price and price history, was supplied by Lipper,
Scandion Oncology A/S Ordinary Shares SCOL Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive
Historical prices; Other instruments Trade Reports . SCOL, Scandion Oncology, (DK0061031895) Trading; Note that the company may have other share series
At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. Company profile for Scandion Oncology A/S including key executives, insider trading, ownership, revenue and average growth rates.
Trönningeskolan halmstad
18 nov 2020 Market Notice 283/20 – Information regarding the rights issue from Scandion Oncology A/S The last day of trading in the company's shares SCOL including the right 2020 until December 8, 2020 on Spotlight Stock M Scandion Oncology | 774 followers on LinkedIn. Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms in oncology.
4,073.94. NASDAQ. 13,698.38.
Föreläsare om stress
forsikring på bil motor
teoriprov körkort antal rätt
bluetooth mottagare usb
fredrik svanberg trubadur
24 helsingborg
håkan nesser barbarotti serien
Investor overview Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy. What makes Scandion Oncology an attractive company for investors? Limited investment horizon: Clinical Phase II studies will be completed within few years after investment. Potential high return: Detailed
Bolaget utvecklar läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier visat sig förbättra effekten av viss standardcancerbehandling. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn.
Ungefär hur stor del av alla gående som skadas i trafiken befinner sig på ett övergångsställe_
chf 3300
Sanionas spin-out Scandion Oncology får godkännande att noteras på Spotlight Stock Market. Saniona, ett ledande biomedicinbolag inom
Limited investment horizon: Clinical Phase II studies will be completed within few years after investment. Potential high return: Detailed Shares in Scandion Oncology A/s are currently trading close to a 52 week high, with the share price up by around 29.3% to 72 over the past week. On a one-month basis, the Scandion Oncology A/s price has risen by 90.8%. Latest Scandion Oncology A/S (SCOL:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Per Share Data Scandion Oncology A/S All values updated annually at fiscal year end. Earnings Per Share-1.17: with the exception of the current price and price history, was supplied by Lipper, Scandion Oncology A/S Ordinary Shares SCOL Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive Historical prices; Other instruments Trade Reports .
Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
Scandion genomför nu en nyemission på 26 Mkr inför listning på Spotlight The Board of Directors in Scandion Oncology A/S (”Scandion Oncology” or the ”Company”) has today, 16 November 2020, pursuant to the authorization granted by the extraordinary general meeting on 13 November 2020, resolved on a fully guaranteed new share issue of 10,711,848 shares with preferential rights for the Company’s existing shareholders (the ”Rights Issue”).
Forskningsbolaget Scandion Oncology började idag den 8 november att handlas på Spotlight Stock Market.